PTHS Stock Summary and Trading Ideas (Pelthos Therapeutics | AMEX:PTHS)

Pelthos Therapeutics Inc is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.

Pelthos Therapeutics trades on the AMEX stock market under the symbol PTHS.

As of December 19, 2025, PTHS stock price climbed to $25.63 with 29,574 million shares trading.

PTHS has a beta of 4.16, meaning it tends to be more sensitive to market movements. PTHS has a correlation of 0.25 to the broad based SPY ETF.

PTHS has a market cap of $79.11 million. This is considered a Micro Cap stock.

Last quarter Pelthos Therapeutics reported $7 million in Revenue and -$5.30 earnings per share. This beat revenue expectation by $527,200 and missed earnings estimates by -$4.63.

The top ETF exchange traded funds that PTHS belongs to (by Net Assets): VTI, VXF.

PTHS support price is $20.28 and resistance is $25.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PTHS shares will trade within this expected range on the day.